Published in J Clin Invest on December 01, 1986
Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest (1994) 7.25
Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol (2012) 4.52
Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest (1998) 3.17
Platelet-derived growth factor gene expression in human atherosclerotic plaques and normal artery wall. Proc Natl Acad Sci U S A (1988) 2.32
Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest (1988) 2.29
Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab (2008) 1.91
Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc Natl Acad Sci U S A (1994) 1.63
Human interleukin 1 induces interleukin 1 gene expression in human vascular smooth muscle cells. J Exp Med (1987) 1.61
Effect of glucocorticoids, monokines and growth factors on the spontaneously developing responses of the rabbit isolated aorta to des-Arg9-bradykinin. Br J Pharmacol (1988) 1.53
The serpin proteinase inhibitor 9 is an endogenous inhibitor of interleukin 1beta-converting enzyme (caspase-1) activity in human vascular smooth muscle cells. J Exp Med (2000) 1.50
Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest (1990) 1.42
Expression of interleukin 1-inducible genes and production of interleukin 1 by aging human fibroblasts. Proc Natl Acad Sci U S A (1992) 1.34
Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol (1990) 1.32
Expression of endothelial-leukocyte adhesion molecule-1 in elicited late phase allergic reactions. J Clin Invest (1991) 1.25
Cell cycle-dependent interleukin 1 gene expression by cultured glomerular mesangial cells. J Clin Invest (1988) 1.20
Interleukin 1 inhibits contraction of vascular smooth muscle. J Clin Invest (1989) 1.20
Interleukin-1 gene expression in rabbit vascular tissue in vivo. Am J Pathol (1991) 1.19
Increased apolipoprotein E and c-fms gene expression without elevated interleukin 1 or 6 mRNA levels indicates selective activation of macrophage functions in advanced human atheroma. Proc Natl Acad Sci U S A (1992) 1.19
Tumor necrosis factor gene expression in human vascular intimal smooth muscle cells detected by in situ hybridization. Am J Pathol (1990) 1.17
Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding. PLoS One (2009) 1.16
Immune interferon inhibits proliferation and induces 2'-5'-oligoadenylate synthetase gene expression in human vascular smooth muscle cells. J Clin Invest (1989) 1.15
Rous-Whipple Award Lecture. Atherosclerosis: a defense mechanism gone awry. Am J Pathol (1993) 1.15
Development of intimal lesions after leukocyte migration into the vascular wall. Am J Pathol (1989) 1.12
Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. Biochem J (1996) 1.10
Endotoxin activates human vascular smooth muscle cells despite lack of expression of CD14 mRNA or endogenous membrane CD14. Infect Immun (1995) 1.09
Prolonged exposure of rat aorta to low levels of endotoxin in vitro results in impaired contractility. Association with vascular cytokine release. J Clin Invest (1990) 1.08
Long-term reversal of diabetes by the injection of immunoprotected islets. Proc Natl Acad Sci U S A (1993) 1.07
Endotoxin-induced cytokine gene expression in vivo. IV. Expression of interleukin-1 alpha/beta and interleukin-1 receptor antagonist mRNA during endotoxemia and during endotoxin-initiated local acute inflammation. Am J Pathol (1992) 1.00
Interleukin-1, immune activation pathways, and different mechanisms in osteoarthritis and rheumatoid arthritis. Ann Rheum Dis (1991) 1.00
Interleukin-1. Dig Dis Sci (1988) 0.98
Endovascular laser–tissue interactions and biological responses in relation to endovenous laser therapy. Lasers Med Sci (2014) 0.96
Pulse exposure to protein synthesis inhibitors enhances vascular responses to des-Arg9-bradykinin: possible role of interleukin-1. Br J Pharmacol (1991) 0.95
Interleukin 1 regulates heparin-binding growth factor 2 gene expression in vascular smooth muscle cells. Proc Natl Acad Sci U S A (1991) 0.94
Up-regulation of [3H]-des-Arg10-kallidin binding to the bradykinin B1 receptor by interleukin-1 beta in isolated smooth muscle cells: correlation with B1 agonist-induced PGI2 production. Br J Pharmacol (1994) 0.93
Activation of glomerular mesangial cells by gram-negative bacterial cell wall components. Am J Pathol (1988) 0.92
Factor XII-induced mitogenesis is mediated via a distinct signal transduction pathway that activates a mitogen-activated protein kinase. Proc Natl Acad Sci U S A (1996) 0.92
Contribution of vascular cell-derived cytokines to innate and inflammatory pathways in atherogenesis. J Cell Mol Med (2011) 0.86
Functional polymorphism of IL-1 alpha and its potential role in obesity in humans and mice. PLoS One (2011) 0.85
Human vascular smooth muscle cells express interleukin-1beta-converting enzyme (ICE), but inhibit processing of the interleukin-1beta precursor by ICE. J Exp Med (1997) 0.84
Induction of aneurysms in the rat by a stenosing cotton ligature around the inter-renal aorta. Int J Exp Pathol (1994) 0.83
Increased serum concentrations of interleukin-1 beta in patients with coronary artery disease. Heart (1996) 0.83
Role of the sympathetic nervous system in carbon tetrachloride-induced hepatotoxicity and systemic inflammation. PLoS One (2015) 0.80
Interleukin-1 and the effects of cyclooxygenase inhibitors on its biological activities. Bull N Y Acad Med (1989) 0.79
Vascular kinin B(1) and B(2) receptor-mediated effects in the rat isolated perfused kidney - differential regulations. Br J Pharmacol (1999) 0.78
Interleukin-1 associations in inflammatory bowel disease and the enteropathic seronegative spondylarthritis. Auto Immun Highlights (2013) 0.75
The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (1980) 40.02
Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature (1985) 9.94
Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci U S A (1984) 8.84
Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. J Clin Invest (1985) 8.70
Autocrine secretion and malignant transformation of cells. N Engl J Med (1980) 7.49
Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med (1984) 5.89
Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A (1986) 5.83
Leukocyte-endothelial interactions. Blood (1985) 5.59
Ia expression by vascular endothelium is inducible by activated T cells and by human gamma interferon. J Exp Med (1983) 4.92
Interleukin 1: an immunological perspective. Annu Rev Immunol (1985) 4.09
Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest (1983) 3.47
Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol (1986) 3.35
Ability of human leukocytic pyrogen to enhance phytohemagglutinin induced murine thymocyte proliferation. Cell Immunol (1981) 3.22
Self-regulation of procoagulant events on the endothelial cell surface. J Exp Med (1985) 3.16
An update on human interleukin-1: from molecular biology to clinical relevance. J Clin Immunol (1985) 2.90
Production of interleukin 1 by human endothelial cells. J Immunol (1986) 2.27
Control of biologically active interleukin 2 messenger RNA formation in induced human lymphocytes. Proc Natl Acad Sci U S A (1984) 2.17
Prostacyclin synthesis induced in vascular cells by interleukin-1. Science (1985) 2.13
Culture of quiescent arterial smooth muscle cells in a defined serum-free medium. J Cell Physiol (1983) 2.03
Regulation of tubulin and actin mRNA production in rat brain: expression of a new beta-tubulin mRNA with development. Mol Cell Biol (1983) 1.94
Interleukin-1: amino acid sequences, multiple biological activities and comparison with tumor necrosis factor (cachectin). Year Immunol (1986) 1.81
Exaggerated human vascular cell prostaglandin biosynthesis mediated by monocytes: role of monokines and interleukin 1. J Immunol (1985) 1.76
Synthesis and secretion of a mitogenic protein by macrophages: description of a superinduction phenomenon. J Immunol (1977) 1.53
Human endothelial cell cultures: phenotypic modulation by leukocyte interleukins. J Cell Physiol (1985) 1.45
Production of interleukin 1 activity by normal human peripheral blood B lymphocytes. J Immunol (1985) 1.40
Expression of I-region-associated antigen (Ia) and interleukin 1 by subcultured human endothelial cells. Cell Immunol (1985) 1.33
A novel chromatographic procedure for purification of bacterial plasmids. Anal Biochem (1983) 1.14
Endothelium-derived vascular relaxing factor. Hypertension (1985) 0.99
Epidermal cytokines: properties of epidermal cell thymocyte-activating factor (ETAF). Lymphokine Res (1984) 0.98
Differential effects of human interleukin-1 on growth of human fibroblasts and vascular smooth muscle cells. Arteriosclerosis (1985) 0.97
The role of vascular smooth muscle cells in experimental autoimmune vasculitis. I. The initiation of delayed type hypersensitivity angiitis. Am J Pathol (1984) 0.95
Control of human lymphocyte proliferation by soluble factors. Lab Invest (1984) 0.92
The endothelium--astrocyte immune control system of the brain. Springer Semin Immunopathol (1985) 0.92
Growth factors from platelets, monocytes, and endothelium: their role in cell proliferation. Ann N Y Acad Sci (1982) 0.81
Oncogenes and signal transduction. Cell (1991) 14.84
Interleukin-1. Rev Infect Dis (1984) 11.24
Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol (1986) 10.92
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med (1986) 10.91
Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci U S A (1984) 8.84
Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med (1988) 7.96
Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell (1998) 7.46
Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest (1994) 7.25
Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science (1987) 7.22
PDGF-dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells. Cell (1989) 6.26
Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin 1 is required for the expression of receptors for interleukin 2. J Immunol (1984) 5.51
Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest (1988) 5.22
Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med (1984) 5.12
Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest (1995) 5.09
Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest (2000) 4.79
Purification and characterization of phosphoinositide 3-kinase from rat liver. J Biol Chem (1990) 4.75
Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science (1986) 4.25
Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation (1998) 3.89
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood (1994) 3.74
Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science (1997) 3.73
Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA (1996) 3.68
Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol (1987) 3.61
Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest (1998) 3.54
Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. N Engl J Med (1983) 3.49
Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation (2001) 3.47
Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity (1999) 3.43
Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J Clin Invest (1986) 3.43
Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol (1986) 3.35
Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature (1998) 3.31
Ability of human leukocytic pyrogen to enhance phytohemagglutinin induced murine thymocyte proliferation. Cell Immunol (1981) 3.22
IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A (2001) 3.21
Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest (1998) 3.17
Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc Natl Acad Sci U S A (1977) 3.15
Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. J Biol Chem (1993) 3.14
Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology (2007) 3.12
Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. JAMA (1994) 3.11
Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. J Clin Invest (1986) 3.05
Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol (1998) 3.04
Demonstration and characterization of two distinct human leukocytic pyrogens. J Exp Med (1974) 2.98
An update on human interleukin-1: from molecular biology to clinical relevance. J Clin Immunol (1985) 2.90
Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science (1988) 2.87
Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest (1990) 2.86
Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL-1. J Exp Med (1985) 2.84
Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest (2001) 2.84
Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science (1986) 2.83
Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colony-stimulating activity and prostaglandin E2. J Clin Invest (1986) 2.82
Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1). J Clin Immunol (1999) 2.79
Lymphokines. N Engl J Med (1987) 2.77
An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb (1993) 2.77
The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci (2001) 2.75
Isolation of an interleukin-1-like factor from human joint effusions. Arthritis Rheum (1983) 2.75
Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation (1999) 2.73
Identification and quantification of polyphosphoinositides produced in response to platelet-derived growth factor stimulation. Methods Enzymol (1991) 2.69
Molecular basis of fever in humans. Am J Med (1982) 2.69
Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol (1986) 2.68
Adherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen. J Exp Med (1979) 2.64
Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol (2001) 2.63
Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med (1999) 2.63
Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation (1998) 2.63
Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc Natl Acad Sci U S A (1999) 2.57
Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A (1997) 2.56
Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme. Am J Pathol (1995) 2.54
Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation (2001) 2.53
A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J (1991) 2.52
Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. J Immunol (2000) 2.50
Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. N Engl J Med (1996) 2.49
Human leukocytic pyrogen induces release of specific granule contents from human neutrophils. J Clin Invest (1978) 2.48
Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res (1994) 2.46
IL-1 induction-capacity of defined lipopolysaccharide partial structures. J Immunol (1989) 2.41
Acute toxoplasmosis leads to lethal overproduction of Th1 cytokines. J Immunol (2001) 2.41
Tumour necrosis factor production in Falciparum malaria and its association with schizont rupture. Clin Exp Immunol (1989) 2.41
Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res (1998) 2.39
Human vascular smooth muscle cells. Target for and source of tumor necrosis factor. J Immunol (1989) 2.39
Quantification of mRNA by polymerase chain reaction (PCR) using an internal standard and a nonradioactive detection method. Methods Mol Biol (1998) 2.39
IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today (1997) 2.37
Enhancement of growth of virulent strains of Escherichia coli by interleukin-1. Science (1991) 2.37
Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med (1974) 2.35
Chemotactic cytokines: the role of leukocytic pyrogen and epidermal cell thymocyte-activating factor in neutrophil chemotaxis. J Immunol (1984) 2.34
Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation (1999) 2.33
Induction of human interleukin-1 by a product of Staphylococcus aureus associated with toxic shock syndrome. J Clin Invest (1984) 2.33
Reduction of experimental myocardial infarct size by corticosteroid administration. J Clin Invest (1973) 2.28
Acute inflammation and a Shwartzman-like reaction induced by interleukin-1 and tumor necrosis factor. Synergistic action of the cytokines in the induction of inflammation and microvascular injury. Am J Pathol (1987) 2.27
A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci U S A (1988) 2.22
Interleukin-1 immunoreactive innervation of the human hypothalamus. Science (1988) 2.22
Role of arachidonate metabolism in the immunoregulatory function of human leukocytic pyrogen/lymphocyte-activating factor/interleukin 1. J Immunol (1983) 2.20
Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol (1992) 2.19
Precordial S-T segment elevation mapping: an atraumatic method for assessing alterations in the extent of myocardial ischemic injury. The effects of pharmacologic and hemodynamic interventions. Am J Cardiol (1972) 2.19
Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli. J Clin Invest (1991) 2.17
Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest (1999) 2.16
Multiple biological activities of human recombinant interleukin 1. J Clin Invest (1986) 2.16
Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol (2001) 2.16
Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor alpha and IL-18. Proc Natl Acad Sci U S A (2000) 2.14